Devices industry more hopeful of escaping pharma review
This article was originally published in Clinica
The EU medical devices industry is optimistic that the most recent amendments to the European Commission proposal on the review of EU pharmaceutical legislation is more favourable to the medical devices industry than earlier versions and proposed amendments to the text.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.